Sedation Regimens for TAVR Recovery

This trial explores how different sedation medications used during transcatheter aortic valve replacement (TAVR) impact recovery. Researchers compare three sedation options—propofol, dexmedetomidine, and a combination of midazolam with fentanyl—to determine which might enhance the recovery experience immediately after the procedure. Ideal participants are those scheduled for a TAVR who can communicate in English or Spanish and have agreed to participate in the study. As a Phase 4 trial, the sedation options are already FDA-approved and proven effective, and this research aims to understand how they benefit more patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have shown that propofol does not significantly differ in surgery or recovery outcomes compared to other sedatives for TAVR patients. However, it may cause more instances of low blood oxygen levels than other options.

Dexmedetomidine reduces confusion after surgery but may lead to low blood pressure and a slow heart rate. Despite these risks, it remains a good alternative with results similar to propofol.

Research indicates that using midazolam and fentanyl in TAVR is safe, typically not leading to major complications during the procedure.

Researchers are excited about these sedation regimens for TAVR recovery because they offer diverse approaches to patient care during surgery. Unlike traditional sedation methods, which often rely heavily on a single agent, this trial explores the use of propofol, dexmedetomidine, and a combination of midazolam and fentanyl. Propofol is known for its rapid onset and short recovery time, making it ideal for surgeries where quick patient recovery is crucial. Dexmedetomidine provides sedation with less respiratory depression, which can be safer for patients with specific health concerns. Meanwhile, the combination of midazolam and fentanyl offers a synergistic effect that enhances sedation while managing pain effectively. Each regimen offers unique benefits that could potentially improve patient outcomes and safety during TAVR procedures.

This trial will compare different sedation regimens for transcatheter aortic valve replacement (TAVR) recovery. Participants in one arm will receive propofol, which studies have shown to be both effective and safe for TAVR procedures. Another arm will use dexmedetomidine, which research suggests may reduce the risk of delayed brain function recovery compared to propofol, while maintaining similar safety and effectiveness. A third arm will involve a combination of midazolam and fentanyl, which has been used successfully, though it doesn't show a significant difference in recovery compared to other sedation methods. Overall, light sedation (conscious sedation) during TAVR is linked to better recovery than full unconsciousness (general anesthesia).⁴⁶⁷⁸⁹